|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nonetheless, Mad2 expression persists and increases karyotype complexity in Kras tumors.
|
27292643 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In human neoplasms, miR-493-3p and Mad2 expression alterations correlated with advanced ovarian cancer forms and high miR-493-3p levels were associated with reduced survival of ovarian and breast cancer patients with aggressive tumors, especially in the paclitaxel therapy arm.
|
26943585 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MAD2 expression in oral squamous cell carcinoma and its relationship to tumor grade and proliferation.
|
25503128 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we identify a novel regulatory mechanism for Mad2 expression involving miR-28-5p-mediated inhibition of Mad2 translation, and we demonstrate that this mechanism is triggered by inactivation of the tumor suppressor VHL, the most common event in clear cell renal cell carcinoma (ccRCC).
|
24491803 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By integrated bioinformatic analysis and experimental confirmation, we identified MXI1, which has been found to act as a tumor suppressor gene by affecting c‑Myc, as a direct target of miR‑24‑3p and miR‑27a‑3p.
|
23254855 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings suggest that altered p31(Comet):Mad2 expression ratios may provide new insight into altered SAC function and the generation of chromosomal instability in tumors.
|
24131926 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, Max interactor-1 (MXI1), an antagonist of c-Myc that is involved in brain tumor progression, has been reported to be deregulated in a variety of tumors including glioma.
|
24376632 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To determine whether MAD2 expression is associated with chemotherapy resistance in ovarian serous adenocarcinoma, we reviewed tumor samples from 41 cases of ovarian serous adenocarcinoma at Osaka City University Medical School Hospital (Osaka, Japan), 2000-2007.
|
22797604 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Changes in Mad1 and Mad2 levels occur in human cancers, where their expression is regulated by the tumor suppressors p53 and retinoblastoma 1 (RB1).
|
23093575 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It has been reported that overexpression of Mad2 in transgenic mice leads to a wide variety of tumors, and Mad2 overexpression causes lung tumor relapse after oncogene withdrawal.
|
22992948 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mad2 is also repressed by p53 and its upregulation is required for CIN in a p53 mutant tumor model.
|
21665145 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, MAD2-siRNA suppressed the proliferation of SGC7901 cells and inhibited tumour formation in athymic nude mice.
|
20440596 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The MAD2 overexpression was significantly frequent in non-TA sarcomas compared with TA tumors without such atypical or high grade morphology (P = 0.012).
|
18477210 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A significantly high tumor MAD2 immunostaining was associated with the progression of histologic grade and the overall low survival.
|
18715617 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, some mitotic regulators such as MAD2 are either up- or down-regulated depending on the tumor types and, in both cases, these alterations result in chromosomal imbalances and tumor development.
|
17259655 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, continued overexpression of Mad2 is not required for tumor maintenance, unlike the majority of oncogenes studied to date.
|
17189715 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, a significantly higher (p = 0.0419) fold-change of Aurora-A/STK15 mRNA (p = 0.0419), but not Incenp, Survivin, Mad-2 or Cyclin-D1, was observed in sCRC cases with CIN (n = 29) when compared with tumours showing microsatellite instability (MIN, n = 10).
|
16402339 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cross-referencing data with that found in HNSCC, we were able to identify a tumor suppressor gene involved in the c-myc pathway (Mxi1) that was similarly under-expressed in smokers and cancer patients with progressive disease.
|
16885739 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although Mxi1-0 and Mxi1 are coexpressed in both human and mouse cells, the relative levels of Mxi1-0 are higher in primary glioblastoma tumors than in normal brain tissue.
|
15548375 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Concordantly, Mad2 is overexpressed in several tumour types, where it correlates with high E2F activity and poor patient prognosis.
|
15306814 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MAD2 dependent mitotic checkpoint defects in tumorigenesis and tumor cell death: a double edged sword.
|
15254432 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To investigate the expression of tumor suppressor gene p27 and spindle checkpoint gene Mad2 and to demonstrate their expression difference in colorectal cancer and normal mucosa and to evaluate its clinical significance.
|
15457580 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The MXI1 gene at 10q24-25 is another candidate tumor suppressor that has only rarely been studied in melanomas, with conflicting results.
|
14559981 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our findings indicate that Mxi1 can act as a tumour suppressor in human glioblastomas through a molecular mechanism involving the transcriptional down-regulation of cyclin B1 gene expression.
|
11875718 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This gene does not appear to be MXI-1, which has been implicated in some other human tumour types.
|
11401316 |
2001 |